{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,8]],"date-time":"2026-09-08T18:17:16Z","timestamp":1788891436967,"version":"build-2803163510"},"reference-count":62,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2019,3,20]],"date-time":"2019-03-20T00:00:00Z","timestamp":1553040000000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Am J Clin Dermatol"],"published-print":{"date-parts":[[2019,6]]},"DOI":"10.1007\/s40257-019-00428-8","type":"journal-article","created":{"date-parts":[[2019,3,20]],"date-time":"2019-03-20T08:08:34Z","timestamp":1553069314000},"page":"409-422","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":35,"title":["Biologic Therapy in the Treatment of Cutaneous Sarcoidosis: A Literature Review"],"prefix":"10.1007","volume":"20","author":[{"given":"Christina","family":"Dai","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shawn","family":"Shih","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ahmed","family":"Ansari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Young","family":"Kwak","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4141-9468","authenticated-orcid":false,"given":"Naveed","family":"Sami","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2019,3,20]]},"reference":[{"issue":"5","key":"428_CR1","doi-asserted-by":"publisher","first-page":"699 e1","DOI":"10.1016\/j.jaad.2012.02.003","volume":"66","author":"A Haimovic","year":"2012","unstructured":"Haimovic A, Sanchez M, Judson MA, Prystowsky S. Sarcoidosis: a comprehensive review and update for the dermatologist: part I. Cutaneous disease. J Am Acad Dermatol. 2012;66(5):699 e1\u201318 (quiz 717\u20138).","journal-title":"J Am Acad Dermatol."},{"issue":"Suppl 3","key":"428_CR2","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1111\/bjd.12533","volume":"169","author":"A Petit","year":"2013","unstructured":"Petit A, Dadzie OE. Multisystemic diseases and ethnicity: a focus on lupus erythematosus, systemic sclerosis, sarcoidosis and Behcet disease. Br J Dermatol. 2013;169(Suppl 3):1\u201310.","journal-title":"Br J Dermatol."},{"key":"428_CR3","doi-asserted-by":"crossref","unstructured":"Heath CR, David J, Taylor SC. Sarcoidosis: are there differences in your skin of color patients? J Am Acad Dermatol. 2012;66(1):121 e1\u201314.","DOI":"10.1016\/j.jaad.2010.06.068"},{"issue":"10","key":"428_CR4","doi-asserted-by":"publisher","first-page":"1361","DOI":"10.2165\/00003495-200868100-00003","volume":"68","author":"CB Doherty","year":"2008","unstructured":"Doherty CB, Rosen T. Evidence-based therapy for cutaneous sarcoidosis. Drugs. 2008;68(10):1361\u201383.","journal-title":"Drugs."},{"issue":"1","key":"428_CR5","first-page":"69","volume":"72","author":"G Volden","year":"1992","unstructured":"Volden G. Successful treatment of chronic skin diseases with clobetasol propionate and a hydrocolloid occlusive dressing. Acta Dermatovenereol. 1992;72(1):69\u201371.","journal-title":"Acta Dermatovenereol."},{"issue":"3","key":"428_CR6","doi-asserted-by":"publisher","first-page":"334","DOI":"10.1016\/j.clindermatol.2007.03.011","volume":"25","author":"RP Baughman","year":"2007","unstructured":"Baughman RP, Lower EE. Evidence-based therapy for cutaneous sarcoidosis. Clin Dermatol. 2007;25(3):334\u201340.","journal-title":"Clin Dermatol."},{"issue":"5","key":"428_CR7","doi-asserted-by":"publisher","first-page":"416","DOI":"10.1046\/j.1525-1470.2003.20509.x","volume":"20","author":"E Fetil","year":"2003","unstructured":"Fetil E, Ozkan S, Ilknur T, Kavukcu S, Kusku E, Lebe B. Sarcoidosis in a preschooler with only skin and joint involvement. Pediatr Dermatol. 2003;20(5):416\u20138.","journal-title":"Pediatr Dermatol."},{"issue":"5","key":"428_CR8","doi-asserted-by":"publisher","first-page":"765","DOI":"10.1016\/j.jaad.2012.10.056","volume":"68","author":"RJ Pariser","year":"2013","unstructured":"Pariser RJ, Paul J, Hirano S, Torosky C, Smith M. A double-blind, randomized, placebo-controlled trial of adalimumab in the treatment of cutaneous sarcoidosis. J Am Acad Dermatol. 2013;68(5):765\u201373.","journal-title":"J Am Acad Dermatol."},{"issue":"7","key":"428_CR9","doi-asserted-by":"publisher","first-page":"681","DOI":"10.1001\/jamadermatol.2017.1162","volume":"153","author":"V Heidelberger","year":"2017","unstructured":"Heidelberger V, Ingen-Housz-Oro S, Marquet A, Mahevas M, Bessis D, Bouillet L, et al. Efficacy and tolerance of anti-tumor necrosis factor alpha agents in cutaneous sarcoidosis: a French Study of 46 cases. JAMA Dermatol. 2017;153(7):681\u20135.","journal-title":"JAMA Dermatol."},{"issue":"2","key":"428_CR10","doi-asserted-by":"publisher","first-page":"288","DOI":"10.1016\/j.semarthrit.2017.03.005","volume":"47","author":"Y Jamilloux","year":"2017","unstructured":"Jamilloux Y, Cohen-Aubart F, Chapelon-Abric C, Maucort-Boulch D, Marquet A, Perard L, et al. Efficacy and safety of tumor necrosis factor antagonists in refractory sarcoidosis: a multicenter study of 132 patients. Semin Arthr Rheum. 2017;47(2):288\u201394.","journal-title":"Semin Arthr Rheum."},{"issue":"6","key":"428_CR11","doi-asserted-by":"publisher","first-page":"1189","DOI":"10.1183\/09031936.00051907","volume":"31","author":"MA Judson","year":"2008","unstructured":"Judson MA, Baughman RP, Costabel U, Flavin S, Lo KH, Kavuru MS, et al. Efficacy of infliximab in extrapulmonary sarcoidosis: results from a randomised trial. Eur Respir J. 2008;31(6):1189\u201396.","journal-title":"Eur Respir J"},{"issue":"7","key":"428_CR12","doi-asserted-by":"publisher","first-page":"795","DOI":"10.1164\/rccm.200603-402OC","volume":"174","author":"RP Baughman","year":"2006","unstructured":"Baughman RP, Drent M, Kavuru M, Judson MA, Costabel U, du Bois R, et al. Infliximab therapy in patients with chronic sarcoidosis and pulmonary involvement. Am J Respir Crit Care Med. 2006;174(7):795\u2013802.","journal-title":"Am J Respir Crit Care Med."},{"issue":"4","key":"428_CR13","first-page":"289","volume":"32","author":"RP Baughman","year":"2016","unstructured":"Baughman RP, Judson MA, Lower EE, Drent M, Costabel U, Flavin S, et al. Infliximab for chronic cutaneous sarcoidosis: a subset analysis from a double-blind randomized clinical trial. Sarcoidosis Vasc Diffuse Lung Dis. 2016;32(4):289\u201395.","journal-title":"Sarcoidosis Vasc Diffuse Lung Dis"},{"issue":"2","key":"428_CR14","doi-asserted-by":"publisher","first-page":"468","DOI":"10.1378\/chest.08-1347","volume":"135","author":"E Stagaki","year":"2009","unstructured":"Stagaki E, Mountford WK, Lackland DT, Judson MA. The treatment of lupus pernio: results of 116 treatment courses in 54 patients. Chest. 2009;135(2):468\u201376.","journal-title":"Chest."},{"issue":"1","key":"428_CR15","first-page":"70","volume":"18","author":"RP Baughman","year":"2001","unstructured":"Baughman RP, Lower EE. Infliximab for refractory sarcoidosis. Sarcoidosis Vasc Diffuse Lung Dis. 2001;18(1):70\u20134.","journal-title":"Sarcoidosis Vasc Diffuse Lung Dis"},{"issue":"2","key":"428_CR16","doi-asserted-by":"publisher","first-page":"290","DOI":"10.1067\/mjd.2003.228","volume":"48","author":"L Mallbris","year":"2003","unstructured":"Mallbris L, Ljungberg A, Hedblad MA, Larsson P, Stahle-Backdahl M. Progressive cutaneous sarcoidosis responding to anti-tumor necrosis factor-alpha therapy. J Am Acad Dermatol. 2003;48(2):290\u20133.","journal-title":"J Am Acad Dermatol"},{"issue":"6","key":"428_CR17","doi-asserted-by":"publisher","first-page":"1432","DOI":"10.1378\/chest.09-2576","volume":"137","author":"ED Crouser","year":"2010","unstructured":"Crouser ED, Lozanski G, Fox CC, Hauswirth DW, Raveendran R, Julian MW. The CD4+\u2009lymphopenic sarcoidosis phenotype is highly responsive to anti-tumor necrosis factor-{alpha} therapy. Chest. 2010;137(6):1432\u20135.","journal-title":"Chest."},{"issue":"11","key":"428_CR18","doi-asserted-by":"publisher","first-page":"2053","DOI":"10.1016\/j.rmed.2006.02.017","volume":"100","author":"S Saleh","year":"2006","unstructured":"Saleh S, Ghodsian S, Yakimova V, Henderson J, Sharma OP. Effectiveness of infliximab in treating selected patients with sarcoidosis. Respir Med. 2006;100(11):2053\u20139.","journal-title":"Respir Med."},{"key":"428_CR19","doi-asserted-by":"crossref","unstructured":"Chung J, Rosenbach M. Extensive cutaneous sarcoidosis and coexistant Crohn disease with dual response to infliximab: case report and review of the literature. Dermatol Online J. 2014;21(3).","DOI":"10.5070\/D3213023563"},{"issue":"1","key":"428_CR20","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1007\/s13555-012-0011-9","volume":"2","author":"P Tuchinda","year":"2012","unstructured":"Tuchinda P, Bremmer M, Gaspari AA. A case series of refractory cutaneous sarcoidosis successfully treated with infliximab. Dermatol Ther. 2012;2(1):11.","journal-title":"Dermatol Ther"},{"issue":"2","key":"428_CR21","doi-asserted-by":"publisher","first-page":"328","DOI":"10.1016\/j.jaad.2011.05.040","volume":"66","author":"T Sene","year":"2012","unstructured":"Sene T, Juillard C, Rybojad M, Cordoliani F, Lebbe C, Morel P, et al. Infliximab as a steroid-sparing agent in refractory cutaneous sarcoidosis: single-center retrospective study of 9 patients. J Am Acad Dermatol. 2012;66(2):328\u201332.","journal-title":"J Am Acad Dermatol."},{"key":"428_CR22","doi-asserted-by":"publisher","first-page":"216939","DOI":"10.1155\/2013\/216939","volume":"2013","author":"B Cerniglia","year":"2013","unstructured":"Cerniglia B, Judson MA. Infliximab-induced hypothyroidism: a novel case and postulations concerning the mechanism. Case Rep Med. 2013;2013:216939.","journal-title":"Case Rep Med."},{"issue":"4","key":"428_CR23","doi-asserted-by":"publisher","first-page":"279","DOI":"10.1111\/ajd.12056","volume":"55","author":"J Tu","year":"2014","unstructured":"Tu J, Chan J. Cutaneous sarcoidosis and infliximab: evidence for efficacy in refractory disease. Australas J Dermatol. 2014;55(4):279\u201381.","journal-title":"Australas J Dermatol."},{"issue":"5","key":"428_CR24","doi-asserted-by":"publisher","first-page":"788","DOI":"10.1002\/art.21468","volume":"53","author":"NJ Sweiss","year":"2005","unstructured":"Sweiss NJ, Welsch MJ, Curran JJ, Ellman MH. Tumor necrosis factor inhibition as a novel treatment for refractory sarcoidosis. Arthr Rheum. 2005;53(5):788\u201391.","journal-title":"Arthr Rheum."},{"issue":"3","key":"428_CR25","doi-asserted-by":"crossref","first-page":"14","DOI":"10.5070\/D33N87W6H3","volume":"13","author":"T Rosen","year":"2007","unstructured":"Rosen T, Doherty C. Successful long-term management of refractory cutaneous and upper airway sarcoidosis with periodic infliximab infusion. Dermatol Online J. 2007;13(3):14.","journal-title":"Dermatol Online J."},{"issue":"8","key":"428_CR26","doi-asserted-by":"publisher","first-page":"e321","DOI":"10.1111\/ijd.12861","volume":"54","author":"R Blanco","year":"2015","unstructured":"Blanco R, Gonzalez-Gay MA, Gonzalez-Lopez MA, Fernandez-Llaca H, Gonzalez-Vela MC. Refractory highly disfiguring lupus pernio: a dramatic and prolonged response to infliximab. Int J Dermatol. 2015;54(8):e321\u20132.","journal-title":"Int J Dermatol."},{"issue":"1","key":"428_CR27","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1159\/000221005","volume":"219","author":"AM Thielen","year":"2009","unstructured":"Thielen AM, Barde C, Saurat JH, Laffitte E. Refractory chronic cutaneous sarcoidosis responsive to dose escalation of TNF-alpha antagonists. Dermatology. 2009;219(1):59\u201362.","journal-title":"Dermatology."},{"issue":"9","key":"428_CR28","doi-asserted-by":"publisher","first-page":"1097","DOI":"10.1001\/archdermatol.2012.1322","volume":"148","author":"KA Wanat","year":"2012","unstructured":"Wanat KA, Rosenbach M. Case series demonstrating improvement in chronic cutaneous sarcoidosis following treatment with TNF inhibitors. Arch Dermatol. 2012;148(9):1097\u2013100.","journal-title":"Arch Dermatol."},{"issue":"4","key":"428_CR29","doi-asserted-by":"publisher","first-page":"522","DOI":"10.1111\/j.1440-1843.2009.01518.x","volume":"14","author":"E Panselinas","year":"2009","unstructured":"Panselinas E, Rodgers JK, Judson MA. Clinical outcomes in sarcoidosis after cessation of infliximab treatment. Respirology. 2009;14(4):522\u20138.","journal-title":"Respirology."},{"issue":"7","key":"428_CR30","doi-asserted-by":"publisher","first-page":"910","DOI":"10.1001\/archderm.141.7.910","volume":"141","author":"MP Heffernan","year":"2005","unstructured":"Heffernan MP, Anadkat MJ. Recalcitrant cutaneous sarcoidosis responding to infliximab. Arch Dermatol. 2005;141(7):910\u20131.","journal-title":"Arch Dermatol."},{"issue":"1","key":"428_CR31","doi-asserted-by":"publisher","first-page":"146","DOI":"10.1111\/j.1365-2133.2004.05769.x","volume":"150","author":"H Haley","year":"2004","unstructured":"Haley H, Cantrell W, Smith K. Infliximab therapy for sarcoidosis (lupus pernio). Br J Dermatol. 2004;150(1):146\u20139.","journal-title":"Br J Dermatol."},{"issue":"1","key":"428_CR32","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1016\/j.semarthrit.2011.12.006","volume":"42","author":"JR Maneiro","year":"2012","unstructured":"Maneiro JR, Salgado E, Gomez-Reino JJ, Carmona L. Efficacy and safety of TNF antagonists in sarcoidosis: data from the Spanish registry of biologics BIOBADASER and a systematic review. Semin Arthr Rheum. 2012;42(1):89\u2013103.","journal-title":"Semin Arthr Rheum."},{"issue":"7","key":"428_CR33","doi-asserted-by":"publisher","first-page":"685","DOI":"10.1016\/j.rmr.2010.06.011","volume":"27","author":"F Jounieaux","year":"2010","unstructured":"Jounieaux F, Chapelon C, Valeyre D, Israel Biet D, Cottin V, Tazi A, et al. Infliximab treatment for chronic sarcoidosis: a case series (in French). Revue Mal Respir. 2010;27(7):685\u201392.","journal-title":"Revue Mal Respir."},{"issue":"1","key":"428_CR34","doi-asserted-by":"publisher","first-page":"27","DOI":"10.7326\/0003-4819-135-1-200107030-00010","volume":"135","author":"AM Yee","year":"2001","unstructured":"Yee AM, Pochapin MB. Treatment of complicated sarcoidosis with infliximab anti-tumor necrosis factor-alpha therapy. Ann Intern Med. 2001;135(1):27\u201331.","journal-title":"Ann Intern Med."},{"issue":"1","key":"428_CR35","first-page":"17","volume":"142","author":"MP Heffernan","year":"2006","unstructured":"Heffernan MP, Smith DI. Adalimumab for treatment of cutaneous sarcoidosis. Arch Dermatol. 2006;142(1):17\u20139.","journal-title":"Arch Dermatol."},{"issue":"1","key":"428_CR36","first-page":"80","volume":"16","author":"A Mirzaei","year":"2017","unstructured":"Mirzaei A, Joharimoghadam MM, Zabihiyeganeh M. Adalimumab-responsive refractory sarcoidosis following multiple eyebrow tattoos: a case report. Tanaffos. 2017;16(1):80\u20133.","journal-title":"Tanaffos."},{"issue":"2","key":"428_CR37","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1159\/000328796","volume":"3","author":"CA Kaiser","year":"2011","unstructured":"Kaiser CA, Cozzio A, Hofbauer GF, Kamarashev J, French LE, Navarini AA. Disfiguring annular sarcoidosis improved by adalimumab. Case Rep Dermatol. 2011;3(2):103\u20136.","journal-title":"Case Rep Dermatol."},{"issue":"5","key":"428_CR38","doi-asserted-by":"publisher","first-page":"917","DOI":"10.1016\/j.jaad.2005.02.023","volume":"53","author":"MA Philips","year":"2005","unstructured":"Philips MA, Lynch J, Azmi FH. Ulcerative cutaneous sarcoidosis responding to adalimumab. J Am Acad Dermatol. 2005;53(5):917.","journal-title":"J Am Acad Dermatol."},{"issue":"7","key":"428_CR39","doi-asserted-by":"publisher","first-page":"795","DOI":"10.1111\/j.1365-2230.2010.03829.x","volume":"35","author":"S Field","year":"2010","unstructured":"Field S, Regan AO, Sheahan K, Collins P. Recalcitrant cutaneous sarcoidosis responding to adalimumab but not to etanercept. Clin Exp Dermatol. 2010;35(7):795\u20136.","journal-title":"Clin Exp Dermatol."},{"issue":"11","key":"428_CR40","doi-asserted-by":"publisher","first-page":"1332","DOI":"10.1001\/archdermatol.2011.307","volume":"147","author":"MA Judson","year":"2011","unstructured":"Judson MA. Successful treatment of lupus pernio with adalimumab. Arch Dermatol. 2011;147(11):1332\u20133.","journal-title":"Arch Dermatol."},{"issue":"12","key":"428_CR41","first-page":"1305","volume":"16","author":"GF Cohen","year":"2017","unstructured":"Cohen GF, Wolfe CM. Recalcitrant diffuse cutaneous sarcoidosis with perianal involvement responding to adalimumab. J Drugs Dermatol. 2017;16(12):1305\u20136.","journal-title":"J Drugs Dermatol."},{"issue":"9","key":"428_CR42","doi-asserted-by":"publisher","first-page":"866","DOI":"10.1016\/j.jdcr.2018.06.011","volume":"4","author":"CE Hagan","year":"2018","unstructured":"Hagan CE, Offiah M, Brodell RT, Jackson JD. Chronic verrucous sarcoidosis associated with human papillomavirus infection: improvement with adalimumab. JAAD Case Rep. 2018;4(9):866\u20138.","journal-title":"JAAD Case Rep."},{"issue":"6","key":"428_CR43","first-page":"538","volume":"5","author":"C Tuchinda","year":"2006","unstructured":"Tuchinda C, Wong HK. Etanercept for chronic progressive cutaneous sarcoidosis. J Drugs Dermatol. 2006;5(6):538\u201340.","journal-title":"J Drugs Dermatol."},{"issue":"8","key":"428_CR44","first-page":"1864","volume":"30","author":"D Khanna","year":"2003","unstructured":"Khanna D, Liebling MR, Louie JS. Etanercept ameliorates sarcoidosis arthritis and skin disease. J Rheumatol. 2003;30(8):1864\u20137.","journal-title":"J Rheumatol."},{"issue":"1","key":"428_CR45","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1378\/chest.124.1.177","volume":"124","author":"JP Utz","year":"2003","unstructured":"Utz JP, Limper AH, Kalra S, Specks U, Scott JP, Vuk-Pavlovic Z, et al. Etanercept for the treatment of stage II and III progressive pulmonary sarcoidosis. Chest. 2003;124(1):177\u201385.","journal-title":"Chest."},{"issue":"2","key":"428_CR46","doi-asserted-by":"publisher","first-page":"245","DOI":"10.2147\/tcrm.2007.3.2.245","volume":"3","author":"KA Papp","year":"2007","unstructured":"Papp KA. The safety of etanercept for the treatment of plaque psoriasis. Ther Clin Risk Manag. 2007;3(2):245\u201358.","journal-title":"Ther Clin Risk Manag."},{"issue":"5","key":"428_CR47","doi-asserted-by":"publisher","first-page":"1296","DOI":"10.1183\/09031936.00000914","volume":"44","author":"MA Judson","year":"2014","unstructured":"Judson MA, Baughman RP, Costabel U, Drent M, Gibson KF, Raghu G, et al. Safety and efficacy of ustekinumab or golimumab in patients with chronic sarcoidosis. Eur Respir J. 2014;44(5):1296\u2013307.","journal-title":"Eur Respir J."},{"issue":"6","key":"428_CR48","doi-asserted-by":"publisher","first-page":"568","DOI":"10.1212\/WNL.0b013e3181ec7ff9","volume":"75","author":"R Bomprezzi","year":"2010","unstructured":"Bomprezzi R, Pati S, Chansakul C, Vollmer T. A case of neurosarcoidosis successfully treated with rituximab. Neurology. 2010;75(6):568\u201370.","journal-title":"Neurology."},{"issue":"1","key":"428_CR49","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1186\/s12948-015-0025-9","volume":"13","author":"F Cinetto","year":"2015","unstructured":"Cinetto F, Compagno N, Scarpa R, Malipiero G, Agostini C. Rituximab in refractory sarcoidosis: a single centre experience. Clin Mol Allergy. 2015;13(1):19.","journal-title":"Clin Mol Allergy"},{"issue":"4","key":"428_CR50","doi-asserted-by":"publisher","first-page":"e87","DOI":"10.1111\/j.1440-0960.2011.00863.x","volume":"53","author":"E Lamrock","year":"2012","unstructured":"Lamrock E, Brown P. Development of cutaneous sarcoidosis during treatment with tumour necrosis alpha factor antagonists. Australas J Dermatol. 2012;53(4):e87\u201390.","journal-title":"Australas J Dermatol."},{"issue":"3","key":"428_CR51","doi-asserted-by":"publisher","first-page":"e8","DOI":"10.1111\/j.1440-0960.2010.00660.x","volume":"52","author":"S Marcella","year":"2011","unstructured":"Marcella S, Welsh B, Foley P. Development of sarcoidosis during adalimumab therapy for chronic plaque psoriasis. Australas J Dermatol. 2011;52(3):e8\u201311.","journal-title":"Australas J Dermatol."},{"issue":"7","key":"428_CR52","doi-asserted-by":"publisher","first-page":"1346","DOI":"10.1093\/rheumatology\/ker166","volume":"50","author":"J Salvatierra","year":"2011","unstructured":"Salvatierra J, Magro-Checa C, Rosales-Alexander JL, Raya-Alvarez E. Acute sarcoidosis as parotid fever in rheumatoid arthritis under anti-tumor necrosis factor-alpha therapy. Rheumatology (Oxford). 2011;50(7):1346\u20138.","journal-title":"Rheumatology (Oxford)."},{"issue":"3","key":"428_CR53","doi-asserted-by":"publisher","first-page":"234","DOI":"10.1007\/s12325-012-0007-y","volume":"29","author":"MM Bonafede","year":"2012","unstructured":"Bonafede MM, Gandra SR, Watson C, Princic N, Fox KM. Cost per treated patient for etanercept, adalimumab, and infliximab across adult indications: a claims analysis. Adv Ther. 2012;29(3):234\u201348.","journal-title":"Adv Ther."},{"issue":"2","key":"428_CR54","first-page":"143","volume":"25","author":"RG Keijsers","year":"2008","unstructured":"Keijsers RG, Verzijlbergen JF, van Diepen DM, van den Bosch JM, Grutters JC. 18F-FDG PET in sarcoidosis: an observational study in 12 patients treated with infliximab. Sarcoidosis Vasc Diffuse Lung Dis. 2008;25(2):143\u20139.","journal-title":"Sarcoidosis Vasc Diffuse Lung Dis."},{"issue":"1","key":"428_CR55","first-page":"49","volume":"27","author":"NJ Sweiss","year":"2010","unstructured":"Sweiss NJ, Barnathan ES, Lo K, Judson MA, Baughman R. C-reactive protein predicts response to infliximab in patients with chronic sarcoidosis. Sarcoidosis Vasc Diffuse Lung Dis. 2010;27(1):49\u201356.","journal-title":"Sarcoidosis Vasc Diffuse Lung Dis."},{"issue":"26","key":"428_CR56","doi-asserted-by":"publisher","first-page":"2540","DOI":"10.1056\/NEJMoa1805958","volume":"379","author":"W Damsky","year":"2018","unstructured":"Damsky W, Thakral D, Emeagwali N, Galan A, King B. Tofacitinib treatment and molecular analysis of cutaneous sarcoidosis. N Engl J Med. 2018;379(26):2540\u20136.","journal-title":"N Engl J Med."},{"key":"428_CR57","doi-asserted-by":"crossref","unstructured":"Rotenberg C, Besnard V, Brillet PY, Giraudier S, Nunes H, Valeyre D. Dramatic response of refractory sarcoidosis under ruxolitinib in a patient with associated JAK2-mutated polycythemia. Eur Respir J. 2018;52(6).","DOI":"10.1183\/13993003.01482-2018"},{"issue":"2","key":"428_CR58","doi-asserted-by":"publisher","first-page":"168","DOI":"10.1080\/03009742.2017.1393559","volume":"47","author":"M Kono","year":"2018","unstructured":"Kono M, Kono M, Jodo S. A case of refractory acute sarcoid myopathy successfully treated with intravenous immunoglobulin. Scand J Rheumatol. 2018;47(2):168\u20139.","journal-title":"Scand J Rheumatol."},{"issue":"12","key":"428_CR59","doi-asserted-by":"publisher","first-page":"1386","DOI":"10.1111\/imj.13247","volume":"46","author":"MW Linger","year":"2016","unstructured":"Linger MW, van Driel ML, Hollingworth SA. Off-label use of tumour necrosis factor-alpha inhibitors and anakinra at an Australian tertiary hospital. Intern Med J. 2016;46(12):1386\u201391.","journal-title":"Intern Med J."},{"issue":"4","key":"428_CR60","doi-asserted-by":"publisher","first-page":"289","DOI":"10.1136\/practneurol-2015-001112","volume":"15","author":"N Shenoy","year":"2015","unstructured":"Shenoy N, Tesfaye M, Brown J, Simmons N, Weiss D, Meholli M, et al. Corticosteroid-resistant bulbar neurosarcoidosis responsive to intravenous immunoglobulin. Pract Neurol. 2015;15(4):289\u201392.","journal-title":"Pract Neurol."},{"issue":"21","key":"428_CR61","doi-asserted-by":"publisher","first-page":"3061","DOI":"10.2169\/internalmedicine.51.8120","volume":"51","author":"N Awano","year":"2012","unstructured":"Awano N, Inomata M, Kondoh K, Satake K, Kamiya H, Moriya A, et al. Mixed-type multicentric Castleman\u2019s disease developing during a 17-year follow-up of sarcoidosis. Intern Med. 2012;51(21):3061\u20136.","journal-title":"Intern Med."},{"key":"428_CR62","doi-asserted-by":"publisher","unstructured":"Semiz H, Kobak S. Coexistence of sarcoidosis and adult onset Still disease. Reumatol Clin. https:\/\/doi.org\/10.1016\/j.reuma.2017.04.004 (epub 19 May 2017).","DOI":"10.1016\/j.reuma.2017.04.004"}],"container-title":["American Journal of Clinical Dermatology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40257-019-00428-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s40257-019-00428-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40257-019-00428-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,9,14]],"date-time":"2022-09-14T01:25:16Z","timestamp":1663118716000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s40257-019-00428-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,3,20]]},"references-count":62,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2019,6]]}},"alternative-id":["428"],"URL":"https:\/\/doi.org\/10.1007\/s40257-019-00428-8","relation":{},"ISSN":["1175-0561","1179-1888"],"issn-type":[{"value":"1175-0561","type":"print"},{"value":"1179-1888","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,3,20]]},"assertion":[{"value":"20 March 2019","order":1,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with Ethical Standards"}},{"value":"No funding was received for the preparation of this review.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"Christina Dai, Shawn Shih, Ahmed Ansari, and Young Kwak have no conflicts of interest to declare. Naveed Sami was a previous sub-investigator for Centocor clinical trial for sarcoidosis.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}